3SBio Inc (SSRX)

[surf1944]

6:19AM 3SBIO and Panacor Bioscience enter collaboration and license agreement to develop and commercialize Nephoxil for hyperphosphatemia (SSRX) 10.01 : Co announces a collaboration and license agreement with Panacor Bioscience to develop and commercialize its Nephoxil pharmaceutical product for the treatment of hyperphosphatemia in China. Nephoxil (ferric citrate) is a differentiated, iron-based phosphate binder for the treatment of hyperphosphatemia in patients with end stage renal disease. Under the terms of the agreement, Panacor Bioscience will grant 3SBio exclusive commercialization rights to Nephoxil in China. Panacor Bioscience will receive an upfront equity investment of US$1 mln and royalties on future product sales. 3SBio will be responsible for the cost of clinical development, registration, manufacturing and commercialization of Nephoxil in China. The agreement is subject to final approval by Taiwan's regulatory authorities, including the Investment Commission of the Taiwan Ministry of Economic Affairs.